Bryan Stuart
Chief Executive Officer at Atavistik Bio, Inc.
Net worth: 13 882 $ as of 2024-04-29
Profile
Bryan E Stuart is currently the Chief Executive Officer & Director at Atavistik Bio, Inc. He previously served as the President & Chief Executive Officer at Kastle Therapeutics LLC, Yarra Therapeutics LLC, and Fulcrum Therapeutics, Inc. He was also the Chief Corporate Development Officer at EKR Therapeutics, Inc. and the VP-Corporate Development, Merger & Acquisitions at OVATION Pharmaceuticals, Inc. Additionally, he served as the Chief Business Officer at Civitas Therapeutics, Inc. Mr. Stuart received his undergraduate degree from the University of Illinois and his MBA from Kellogg School of Management.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2024-03-30 | 1,947 ( 0.00% ) | 13 882 $ | 2024-04-29 |
Bryan Stuart active positions
Companies | Position | Start |
---|---|---|
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Chief Executive Officer | 2023-07-16 |
Former positions of Bryan Stuart
Companies | Position | End |
---|---|---|
FULCRUM THERAPEUTICS, INC. | Chief Executive Officer | 2023-01-01 |
Yarra Therapeutics LLC | Chief Executive Officer | 2018-07-31 |
Kastle Therapeutics LLC
Kastle Therapeutics LLC Medical/Nursing ServicesHealth Services Kastle Therapeutics LLC develops therapeutics targeted towards patients with high unmet medical needs. The company is headquartered in Chicago, IL. | Chief Executive Officer | 2017-10-31 |
Civitas Therapeutics, Inc.
Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Corporate Officer/Principal | 2014-09-30 |
EKR Therapeutics, Inc.
EKR Therapeutics, Inc. Hospital/Nursing ManagementHealth Services EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. | Corporate Officer/Principal | 2012-05-31 |
Training of Bryan Stuart
University of Illinois | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
FULCRUM THERAPEUTICS, INC. | Health Technology |
Private companies | 6 |
---|---|
EKR Therapeutics, Inc.
EKR Therapeutics, Inc. Hospital/Nursing ManagementHealth Services EKR Therapeutics, Inc. is a specialty pharmaceutical company focused on acquiring, developing and maximizing the potential utility of critical-care hospital products offering broader therapeutic options and greater control to improve in-patient care, speed recovery, and achieve optimal outcomes. Backed by the strength of its award winning management team, the dedication of its field force of product specialists and its commitment to excellence in customer service and medical education, EKR has been organized to be a class leader in commercializing products to address unmet and under-satisfied medical needs or to otherwise enhance the therapeutic value of acute-care products. | Health Services |
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Health Technology |
Civitas Therapeutics, Inc.
Civitas Therapeutics, Inc. BiotechnologyHealth Technology Civitas Therapeutics, Inc. develops transformative pulmonary delivery therapies. The company was founded by Glenn Batchelder, Richard P. Batycky, Martin I. Freed, Jennifer Fujii, Jeffrey Elton and James L. Wright on June 17, 2009 and is headquartered in Ardsley, NY. | Health Technology |
Kastle Therapeutics LLC
Kastle Therapeutics LLC Medical/Nursing ServicesHealth Services Kastle Therapeutics LLC develops therapeutics targeted towards patients with high unmet medical needs. The company is headquartered in Chicago, IL. | Health Services |
Yarra Therapeutics LLC | |
Atavistik Bio, Inc.
Atavistik Bio, Inc. BiotechnologyHealth Technology Atavistik Bio, Inc. is a pre-clinical stage biotechnology company located in an undisclosed location. The American company is pioneering a synthetic, scalable approach to identify and harness highly conserved protein-metabolite interactions to revolutionize small molecule drug discovery. The company's advanced data analytics and AI platforms leverage structure-based drug design to engineer novel, highly specific small molecule drugs to activate, inhibit or stabilize targets. The company is led by an experienced management team and advisors, plus a robust investment syndicate, and is positioned to deliver transformational science to ultimately improve patient care. Atavistik Bio was founded by prominent scientists who are considered among the leading authorities in cell biology, cancer cell biology and cell metabolism. Bryan E Stuart has been the CEO of the company since 2023. | Health Technology |
- Stock Market
- Insiders
- Bryan Stuart